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A B S T R A C T
Purpose: : To develop a clinical prediction model to predict a clinically relevant adrenal disorder for patients
with adrenal incidentaloma.
Materials and methods: : This retrospective study is approved by the institutional review board, with waiver of
informed consent. Natural language processing is used for ﬁltering of adrenal incidentaloma cases in all thoracic
and abdominal CT reports from 2010 till 2012. A total of 635 patients are identiﬁed. Stepwise logistic regression
is used to construct the prediction model. The model predicts if a patient is at risk for malignancy or hormonal
hyperfunction of the adrenal gland at the moment of initial presentation, thus generates a predicted probability
for every individual patient. The prediction model is evaluated on its usefulness in clinical practice using de-
cision curve analysis (DCA) based on diﬀerent threshold probabilities. For patients whose predicted probability
is lower than the predetermined threshold probability, further workup could be omitted.
Results: : A prediction model is successfully developed, with an area under the curve (AUC) of 0.78. Results of
the DCA indicate that up to 11% of patients with an adrenal incidentaloma can be avoided from unnecessary
workup, with a sensitivity of 100% and speciﬁcity of 11%.
Conclusion: : A prediction model can accurately predict if an adrenal incidentaloma patient is at risk for ma-
lignancy or hormonal hyperfunction of the adrenal gland based on initial imaging features and patient demo-
graphics. However, with most adrenal incidentalomas labeled as nonfunctional adrenocortical adenomas re-
quiring no further treatment, it is likely that more patients could be omitting from unnecessary diagnostics.
1. Introduction
An adrenal incidentaloma is an adrenal mass detected on imaging
studies performed for indications other than to evaluate the adrenal
gland [1]. Advances in imaging and the widespread availability of
imaging technology has resulted in detection of an increasing number
of incidental ﬁndings [2]. The prevalence of adrenal incidentalomas
found on computed tomography (CT) scans varies from 2.5% to 4% for
abdominal CT, and 4.2% for thoracic CT, in adult populations [3–5].
This prevalence increases with age, up to 10% at an age of 70 or above
[1,6–8]. As the population ages and the use of imaging technology in-
tensiﬁes, these incidentally discovered tumors would become a more
prevalent diagnostic challenge [1,2,9].
Although most adrenal incidentalomas are nonfunctional
adrenocortical adenomas requiring no further treatment, diagnostic
workup is needed to determine whether these incidental ﬁndings are
malignant or cause hormonal hyperfunction [2,6]. According to current
endocrine and surgical guidelines, every patient is adhered to the same
expensive cascade of tests and procedures [10,11]. This results in sig-
niﬁcant cost. Berland et al. [20,10] recommend biochemical evaluation
only in patients with clinical signs or symptoms of adrenal hyperfunc-
tion [11]. Furthermore, by evaluation of these incidental ﬁndings, pa-
tients are exposed to radiation from the CT, which increases the prob-
ability of cancer [9]. Each patient has a 1 in 430–2170 chance of
developing cancer [9]. Cawood and colleagues showed that this po-
tential risk of cancer is similar to that of the adrenal becoming malig-
nant during the average recommended CT scan follow-up of 3 years.
It is important to identify all adrenal incidentalomas that are
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malignant and/or cause hormonal hyperfunction, but at the same time
avoiding patients from unnecessary workup. Therefore, clinical man-
agement of adrenal incidentaloma should be tailored to the individual
patient. Personalized medicine will help produce more eﬃcient and
eﬀective diagnoses and treatment, and will lead to better prognoses for
patients at both the individual and population level. The availability of
patient- and disease-related data in today’s healthcare workforce is a
signiﬁcant resource in the development and application of this in-
dividual-based approach [12]. Therefore, by using these data pre-
ventive or therapeutic interventions can be concentrated on the patients
who will beneﬁt, and at the same time sparing expense and side eﬀects
for those who will not [13].
The purpose of this retrospective study was to develop a clinical
prediction model to predict clinically relevant adrenal disorder for
patients with adrenal incidentaloma.
2. Materials and methods
2.1. Patient identiﬁcation
This retrospective study is approved by the institutional review
board, with waiver of informed consent. For ﬁltering of potential
adrenal incidentaloma cases, natural language processing (NLP) is used
in all thoracic and abdominal CT reports from 2010 till 2012 from a
query of a searchable database of a major university-aﬃliated hospital.
All patients with initial presentation or imaging workup for adrenal
incidentaloma during this period are identiﬁed. Reports containing key
sentences that mention the adrenal are selected. Non-relevant anatomic
identiﬁers are removed from key sentences, and frequent negative
patterns are subsequently ﬁltered. A machine learning selection algo-
rithm is trained using an annotated set of 500 key sentences and applied
as ﬁnal ﬁlter. By applying the NLP pipeline as proposed by Pons and
colleagues [14], 139,329 radiology reports were removed from the
dataset. Through this pipeline, we managed to increase ﬁnding pre-
valence of potential adrenal incidentaloma [14]. This corresponds with
2122 unique potential adrenal incidentaloma patients (Fig. 1).
2.2. Study population
All adult patients (≥18 years) with an adrenal mass incidentally
found on CT are included in this study. Patients with recorded com-
plaints possibly indicating adrenal disease at the moment of ﬁnding,
patients with a vague described adrenal disorder presumably smaller
than 1 cm in diameter, patients with expected metastasis, and patients
with a history of metastatic disease are not considered to be in-
cidentalomas and are therefore excluded from this study. Song et al.,
found no malignant mass among adrenal incidentalomas in low-risk
patients, therefore patients with a history of malignancy are included
[15]. Patients who were referred from another hospital are excluded, as
no data regarding potential work- and follow-up is available in the
electronic health record at our hospital. After re-measurements of the
remaining incidentalomas, patients with an adrenal mass smaller than
1 cm are excluded.
2.3. Data collection
Patient workup data of all adrenal incidentaloma cases are collected
from the electronical medical record by manual investigation of radi-
ology reports, clinical letters and pathology reports. In addition, med-
ication, lab tests and patient data are acquired from the respective
hospital databases.
2.4. Data analysis: descriptive statistics
For patients included in the study demographical data, the radi-
ological characteristics of the lesion, values of the biochemical
evaluation, and adrenal disorder are recorded. Because tumor size ap-
peared to be lognormally distributed it is log-transformed. Surface of
the nodule is calculated as the surface of an ellipse by using the di-
mensions of the long en short axis and laterality of the nodule. All
patients outcome are veriﬁed with the nationwide network and registry
of histo- and cytopathology in the Netherlands (PALGA).
2.5. Data analysis: predictive modeling
A clinical prediction model is developed to predict if an individual
patient is at risk for a clinically relevant adrenal disorder. Stepwise
logistic regression is used to construct the prediction model by using
age and sex of the patient, the use of anti-hypertensive drugs, history of
malignancy, surface, size and laterality of the nodule. For a total of 10
iterations a validation set is constructed based on a 15% hold-out
sample with the original class distribution. The remaining data is used
for training and tuning of the model using 10-fold cross-validation. The
dataset is heavily imbalanced given that just 5% is clinically relevant.
To overcome the problem of unbalanced data, the synthetic minority
over-sampling technique (SMOTE) is used [16]. Hence a 50-50 class
distribution of the target variable is generated by interpolation between
existing cases. The prediction model predicts, at the presentation of an
adrenal incidentaloma, if a patient is at risk for malignancy or hormonal
hyperfunction of the adrenal gland. The model generates a predicted
probability for every individual patient.
2.6. Model validation
For validation of the prediction model 10-fold cross-validation is
used to better estimate the performance of the model. The performance
metrics used are area under the curve (AUC), cohen’s kappa and area
under kappa (AUK). Cohen’s kappa is chosen for two reasons: [1] it
takes into account the agreement occurring by chance, and [2] it favors
correct classiﬁcation of the minority class over that of the majority
class. These are properties not accounted for by AUC [17]. This is useful
when dealing with an imbalanced dataset where it is more important to
correctly predict the minority class. The performance of the model is
evaluated based on the over-sampled test sets, using a threshold prob-
ability of 50%, as well as the validation dataset with original class
distribution of the target variable.
2.7. Decision curve analysis
The prediction model is evaluated on its usefulness in clinical
practice using decision curve analysis (DCA). DCA is a method for
evaluating the beneﬁts of a diagnostic test across a range of patients
preferences for accepting risk of under- and overtreatment to facilitate
decisions about test selections and use [18]. The prediction model
generates a probability of having a clinically relevant adrenal disorder
for every individual patient. Additional workup is needed to determine
the diagnosis if the likelihood is near one. At some probability between
0 and 1, patients are unsure whether or not the be treated [18].
Threshold probability are determined by a panel of experts and are set
on 1%, 1,5% and 2%. For patients whose predicted probability of the
prediction model is lower than the predetermined threshold prob-
ability, diagnostic workup could be omitted.
3. Results
A total of 2122 potential adrenal incidentalomas are identiﬁed by
using NLP. Of these, 1487 patients are excluded after manual inspection
based on the inclusion and exclusion criteria (Fig. 1). Table 1 displays
patient demographics and diagnostic workup features of the ﬁnal co-
hort of 635 adrenal incidentaloma patients. Patients are predominantly
older, averaging 63 years of age, with more females than males. Almost
one-ﬁfth of these patients (N = 118) used anti-hypertensive drugs at
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the moment of adrenal incidentaloma presentation, and almost 54% of
the patients (N = 341) had a history of malignancy. The median dia-
meter of the lesion was 13 mm with a range of 10–141 mm. Only half of
the 187 patients that received workup, received both biochemical
screening and imaging workup. 32 of 635 patients (5%) had a clinically
relevant adrenal disorder. This included 1 patient with an adrenalcor-
tical carcinoma, 2 patients with a pheochromocytoma, 9 patients with a
hormonal hyperfunction, 16 patients whereby growth of≥ 1 cm of the
Fig. 1. Flowchart study design.
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adrenal gland was determined, and 4 patients who underwent adre-
nalectomy due to tumor size or radiological characteristics.
3.1. Results of prediction model
Stepwise logistic regression resulted in two diﬀerent prediction
models. The number of variables selected for each of the 10 folds of the
10-fold cross-validation are presented in Fig. 2. All 10 folds contained
the variables laterality and surface of the nodule. Half of the 10 folds
contained a third variable, i.e. age. The average coeﬃcients are pre-
sented in Table 2.
3.2. Model validation
ROC and AUK curves are determined and presented in Fig. 3. The
area under the curve (AUC) is 0.78 on both the cross-validation and
validation data. The results of the area under kappa (AUK) and the
Cohen’s Kappa are comparable for both the models. The Cohen's kappa
of the cross-validation shows that the model performs 13,7% better
than if the classiﬁcation was done only by chance. The average per-
formance metrics after 10-fold cross-validation are presented in
Table 3.
3.3. Results of decision curve analysis
The prediction model is evaluated on its usefulness in clinical
practice using DCA based on diﬀerent threshold probabilities. Results of
the DCA are presented in Table 4. A higher threshold probability leads
to higher savings. However, by increasing the threshold probability
from 1,5% to 2%, unnecessary workup is avoided in 23% of the pa-
tients, but patients with clinically relevant adrenal disorder are missed.
Without omitting any clinically relevant patient, the highest possible
threshold probability is 1,7%. Using this threshold probability, un-
necessary workup is avoided in 11% of patients with an adrenal in-
cidentaloma, with a sensitivity of 100% and speciﬁcity of 11%. Fig. 4
shows an added value of the prediction model at 3%. At a lower
threshold probability the model does not diﬀer from treating all pa-
tients.
4. Discussion
This research resulted in a prediction model for patient-speciﬁc
workup of adrenal incidentalomas. Our ﬁndings demonstrate that a
prediction model for predicting a clinically relevant outcome of adrenal
incidentalomas is a solution for avoiding patients from unnecessary
workup. Hereby, management of this growing groups of patient can be
tailored to the individual patient what will lead to reduced risks and
monetary saving [11]. However, the number of patients avoiding from
unnecessary workup depends on the predetermined threshold prob-
ability of the decision curve analysis (DCA). A higher threshold prob-
ability leads to higher savings, but will increase the chance of omitting
patients with adrenal disorder, adrenalcortical carcinoma, pheochro-
mocytoma or hyperfunction adrenal lesion, from workup.
A prediction model is successfully developed with an AUC of 0.78,
including age and sex of the patient, the use of anti-hypertensive drugs,
history of malignancy, surface, size and laterality of the nodule. Results
of the DCA indicate that up to 11% of patients with an adrenal in-
cidentaloma can be avoided from unnecessary workup, with a sensi-
tivity of 100%. In contrast to the AACE/AAES guideline, these patients
will not receive any workup [19]. By increasing the corresponding
threshold probability of 1,7%, patients with clinically relevant adrenal
disorder will be missed and omitted from necessary workup, with all its
consequences. Furthermore, the DCA shows no added value of the
prediction model at this threshold probability, i.e. the model does not
Table 1
Patient demographics and initial imaging features (n = 635).
Variable N (%)
Patient demographics





Use of anti-hypertensive drugs 118 (18.6)
History of malignancy 341 (53.7)
Radiological characteristics
Surface nodule (mm) 267,8 (538,2)*
Range 57,7–12556*
Nodule size (mm) 19,6 (8,9)*
Range Categories nodule size 10–141*
<40 mm 626 (98.6)
40–60 mm 6 (0,9)





Biochemical screening 21 (3,3)
Imaging workup (non-contrast CT) 78 (12.3)
Biochemical screening and imaging workup 88 (13.9)
Adrenal disorders
Adrenalcortical carcinoma 1 (0,2)
Pheochromocytoma 2 (0,3)
Subclinical Cushing’s syndrome 4 (0,6)
Cushing’s syndrome (subclinical) 4 (0,6)
Primary aldosteronism 1 (0,2)
Growth of≥ 1 cm 17 (2,7)
Adrenalectomy due to tumor size 3 (0,5)
**Surface of the nodule is calculated as the surface of an ellipse by using the dimensions of
the long en short axis.
* These values are presented as mean (± SD).
Fig. 2. Selected variables for 10-fold cross-validation on the validation data.
Table 2
Coeﬃcients 10-fold cross-validation on the validation data.
Model B Std. Error t Sig.
1 (Constant) −2.550 0.380 −6.710 0.000
laterality −1.224 0.420 −3.396 0.000
Surface 0.002 0.001 3.488 0.001
2 (Constant) 0.264 3.313 0.199 0.825
laterality −1.454 0.362 −3.340 0.000
Surface 0.002 0.001 3.415 0.001
Age −0.043 0.020 −2.146 0.033
a. Dependent variable: clinically relevant adrenal disorder.
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Fig. 3. The ROC curves (a) and AUK curves (b) of the








Results decision curve analysis.
Threshold probability Patients avoided from workup Sensitivity Speciﬁcity
1% 2% 100% 2%
1,5% 7% 100% 7%
2% 23% 90% 24%
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diﬀer from treating all patients.
How to workup patients with adrenal incidentaloma is a con-
troversial issue. Workup strategies range from a minimalist approach
using a single scan within 6 months while most recommend annual CT
scanning for up to 4 or 5 years [20]. There have been attempts to make
the current management algorithm more speciﬁc by incorporating a
risk stratiﬁcation algorithm to leave less room for subjective decision
making. Birsen and colleagues used tumor size and Houndsﬁeld units
(HU) density on noncontrast CT as parameter for decision making [21].
In our research we used a prediction model for decision making. The
prediction model uses statistical and machine learning algorithms
which have been applied successfully in various ﬁelds [22].
Our study had an important limitation that is inherent to retro-
spectively designed studies; i.e. the availability of clinical data. At
Erasmus Medical Center management of the adrenal incidentaloma is
highly variable in terms of guideline adherence. This resulted in only a
small group of patients that received diagnostic workup. Furthermore,
not all initial imaging ﬁndings were accurate reported in the electro-
nical medical record. To reduce missing data all patients outcome were
veriﬁed and all adrenal incidentalomas were remeasured. While only
5% of this patient group has a clinically relevant adrenal disorder, it is
likely that more patients could be omitting from unnecessary diag-
nostics. With more imaging features, e.g. tumor size during follow-up
and HU of the noncontrast CT, it can be determined whether and how
often imaging scanning is necessary during the workup period for every
individual patient. In this manner, a better individualized workup can
be achieved what results in a more appropriate use of existing diag-
nostics. Furthermore, the performance on the validation set was highly
ﬂuctuating. This is due to the imbalanced distribution of the data. This
skewed distribution is inherent in health care, where other models
could be more suitable in order to deal with this problem. Moreover,
the model was developed and validated using internal data from the
Erasmus Medical Center. In order to ensure general applicability of the
prediction model external validation is essential.
Not all adrenal incidentaloma patients should adhere to the same
cascade of test and procedures. Instead, during the diagnostic workup
clinicians should make considered decisions to stop or continue workup
for every individual patient. By implementing the prediction model in
clinical practice both radiologists and referring physicians can be sup-
ported by these decisions.
To support decision making in clinical routine, integration of the
prediction model is necessary. This form of clinical decision support can
be used to tailor diagnostic algorithms to individual patients and will
provide actionable information and suggestions for clinicians, based on
evidence rather than intuition or habit [22–25]. This is closely related
to the concept of integrated diagnostics, the convergence of imaging,
pathology, and laboratory tests with advanced information technology
(IT), what could increase the quality and eﬃciency of healthcare [26].
For the model to become common clinical practice enormous ad-
vancement in the IT infrastructure and the EHR are required [23]. For
example, structured reporting is needed to share information among
disciplines and facilitate the development of reproducible algorithms to
integrate data from diverse sources [26].
In conclusion, a prediction model can accurately predict if an
adrenal incidentaloma patient is at risk for malignancy or hormonal
hyperfunction of the adrenal gland based on initial imaging features
and patient demographics. The model can support clinicians to tailor
diagnostic workup to the individual patient. However, savings are
small. With most adrenal incidentalomas labeled as nonfunctional
adrenocortical adenomas requiring no further treatment, it is likely that
more patients could be omitting from unnecessary diagnostics.
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